AstraZeneca

200 articles with AstraZeneca

• ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

  5/29/2020

  Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® achieved a clinically meaningful tumor response in patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer whose disease had progressed following one or more systemic therapies.

• ENHERTU (fam-trastuzumab deruxtecan-nxki) Significantly Improved Tumor Response Rate and Overall Survival in HER2-positive Metastatic Gastric Cancer in Phase II DESTINY-Gastric01 Trial

  5/29/2020

  Detailed results from the positive registrational, randomized controlled Phase II DESTINY-Gastric01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s (Daiichi Sankyo) ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in objective response rate (ORR) and overall survival (OS),

• ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01

  5/29/2020

  Results from the ongoing Phase II DESTINY-CRC01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

• AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2

  5/29/2020

  AVEO Oncology announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA®, the Company’s once-daily, potent and selective next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with IMFINZI®...

• TAGRISSO Demonstrated Unprecedented Patient Benefit in the Adjuvant Treatment of EGFR-Mutated Lung Cancer

  5/28/2020

  Detailed results from the Phase III ADAURA trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (Stage IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

• ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)

  5/26/2020

  AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies

• LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone

  5/20/2020

  Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA or ATM Mutations, A Key Secondary Endpoint in the Phase 3 PROfound Trial

• LYNPARZA® (Olaparib) Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

  5/20/2020

  Only PARP inhibitor to improve overall survival vs enzalutamide or abiraterone in the biomarker-based subset of prostate cancer patients with BRCA1/2 or ATM mutations

• MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors

  5/19/2020

  MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the appointment of Dr. James Mackay to its Board of Directors.

• ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer

  5/18/2020

  Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Breakthrough Therapy Designation in the U.S.

• ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Mutant Metastatic Non-Small Cell Lung Cancer

  5/18/2020

  AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

• CELLINK announces collaboration with AstraZeneca to utilize CELLINKs’ 3D-bioprinting technology for liver organoid culture

  5/14/2020

  CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.

• AstraZeneca Advances the Science of Cancer Medicine With Practice-Changing Data at the ASCO20 Virtual Scientific Program

  5/13/2020

  AstraZeneca will present ground-breaking new results across its broad portfolio of cancer medicines during the 2020 American Society of Clinical Oncology ASCO20 Virtual Scientific Program, May 29 to May 31, 2020.

• LYNPARZA (Olaparib) Approved in US as 1st-line Maintenance Treatment With bevacizumab For HRD-Positive Advanced Ovarian Cancer

  5/11/2020

  Patients treated with LYNPARZA and bevacizumab lived without disease progression for 37.2 months vs. 17.7 months median for bevacizumab alone

• ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric Cancer

  5/11/2020

  Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Breakthrough Therapy Designation in the U.S. for the treatment of patients with HER2 positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.

• ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Positive Metastatic Gastric Cancer

  5/11/2020

  AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received two or more prior regimens including trastuzumab.

• LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

  5/8/2020

  AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian,

• FARXIGA Approved in the US for the Treatment of Heart Failure in Patients With Heart Failure With Reduced Ejection Fraction

  5/6/2020

  FARXIGA is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalization for heart failure

• imre Health Grows Medical & Scientific Affairs in 2020

  5/5/2020

   imre Health, an independent, integrated marketing and communications agency, welcomes Shane McDevitt, PhD, to lead its Medical and Scientific Affairs group. Shane is one of the several recent senior hires, including Josh Simon, VP of Social Marketing, who joined the team in 2020 from AstraZeneca, to help better evolve the agency's strategy and digital-led service offerings.

• Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate

  4/30/2020

  Vaccitech Ltd and the University of Oxford announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the University.